多形神経膠芽腫(GBM)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0635
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:2467
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2019, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 127, 81, 1, 10, 198, 36 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 15, 3, 52 and 9 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Glioblastoma Multiforme (GBM) – Overview
Glioblastoma Multiforme (GBM) – Therapeutics Development
Glioblastoma Multiforme (GBM) – Therapeutics Assessment
Glioblastoma Multiforme (GBM) – Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) – Drug Profiles
Glioblastoma Multiforme (GBM) – Dormant Projects
Glioblastoma Multiforme (GBM) – Discontinued Products
Glioblastoma Multiforme (GBM) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019

【掲載企業】

1st Bio Therapeutics Inc
4D Pharma Plc
Aadi Bioscience Inc
AbbVie Inc
ABM Therapeutics Inc
Accendatech Au Pty Ltd
Actuate Therapeutics Inc
Adastra Pharmaceuticals Inc
Adlai Nortye Biopharma Co Ltd
Aduro BioTech Inc
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Aettis Inc
Agenus Inc
AiVita Biomedical Inc
Allianz Pharmascience Ltd
Alterity Therapeutics Ltd
Amal Therapeutics SA
Amasa Technologies Inc
Ambrx Inc
Amgen Inc
AmpliPharm Pharmaceuticals LLC
Anchiano Therapeutics Ltd
Anew Oncology Inc
AngioChem Inc
Apac Biotech Pvt Ltd
apceth Biopharma GmbH
Apexigen Inc
APIM Therapeutics AS
Apogenix AG
Apollomics Inc
Apotex Inc
Aptamer Sciences Inc
Argonaut Therapeutics Ltd
Arizona Cancer Therapeutics LLC
Arog Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Arrogene Inc
Astellas Pharma Inc
AstraZeneca Plc
Athenex Inc
Aurora BioPharma Inc
Avalia Immunotherapies Ltd
Aveta Biomics Inc
Avid Chemotherapeutics LLC
Avidin Ltd
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bayer AG
BeiGene Ltd
Beijing Eastern Biotech Co Ltd
Berg LLC
BerGenBio ASA
Bexion Pharmaceuticals LLC
BeyondBio Inc
BeyondSpring Inc
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
Bioasis Technologies Inc
BioIntegrator Ltd
Biosion Inc
Biovista Inc
BioXpress Therapeutics SA
Black Diamond Therapeutics Inc
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Boston Biomedical Inc
Breakpoint Therapeutics GmbH
Bristol-Myers Squibb Co
Candel Therapeutics
Cantex Pharmaceuticals Inc
CARsgen Therapeutics Ltd
CDG Therapeutics Inc
Cell Medicine Cooperation
CellCure
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellivery Therapeutics Inc
Cellmid Ltd
Celsion Corp
Celularity Inc
CHA Bio & Diostech Co Ltd
CNS Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
Curtana Pharmaceuticals Inc
Cynata Therapeutics Ltd
CytoVac AS
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
Deciphera Pharmaceuticals Inc
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Denovo Biopharma LLC
DevaCell Inc
Diakonos Research Ltd
Diffusion Pharmaceuticals Inc
Diverse Biotech Inc
Divide and Conquer Ltd
DNAtrix Inc
Dong-A ST Co Ltd
DrugCendR Inc
DualTpharma BV
Ecrins Therapeutics SAS
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Empirica Therapeutics Inc
ENB Therapeutics LLC
EnduRx Pharmaceuticals Inc
EnGeneIC Ltd
Enochian Biosciences Inc
Enterome Bioscience SA
EntreChem SL
EpicentRx Inc
EpiDrugs Discovery
Epigene Therapeutics Inc
Epygen Biotech Pvt Ltd
ERC Belgium SA
Erytech Pharma SA
Eutilex Co Ltd
Ever Supreme Bio Technology Co Ltd
Everfront Biotech Inc
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Falcon Therapeutics Inc
Faron Pharmaceuticals Oy
Felicitex Therapeutics Inc
FirstString Research Inc
Flag Therapeutics Inc
Flavocure Biotech LLC
Fujifilm Holdings Corp
Fusion Antibodies Plc
Galapagos NV
GC Pharma
Gene Techno Science Co Ltd
Geneius Biotechnology Inc
Genenta Science srl
Genentech Inc
Genexine Inc
Genisphere LLC
Genoscience Pharma
Gilead Sciences Inc
GlaxoSmithKline Plc
GlioCure SAS
GlioPharma ApS
GO Therapeutics Inc
GtreeBNT Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
GW Pharmaceuticals Plc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
Hope Biosciences LLC
HOX Therapeutics Ltd
Humanigen Inc
Hutchison MediPharma Ltd
Hyperstem Therapeutics Inc
i2 Pharmaceuticals Inc
Ibex Biosciences LLC
Immatics Biotechnologies GmbH
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitor LLC
ImmunityBio Inc
ImmunoCellular Therapeutics Ltd
Immunomedics Inc
Immunomet Therapeutics Inc
Immunomic Therapeutics Inc
IMV Inc
Imvax Inc
Incysus Therapeutics Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Innovate Biopharmacueticals Inc
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
InSight Biopharmaceuticals Ltd
Instituto Biomar SA
Insys Therapeutics Inc
Intensity Therapeutics Inc
Ipsen SA
ISA Pharmaceuticals BV
Istari Oncology Inc
Janpix Inc
Jay Pharma Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jubilant Biosys Ltd
Juno Therapeutics Inc
JW CreaGene Co Ltd
Kadmon Corp LLC
Kalgene Pharmaceuticals Inc
Kancera AB
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Komipharm International Co Ltd
Kringle Pharma Inc
Kyorin Pharmaceutical Co Ltd
Lacerta Therapeutics Inc
Lauren Sciences LLC
Legend Biotech USA Inc
Lin Bioscience Inc
Lipopharma Therapeutics SL
Lixte Biotechnology Holdings Inc
MacroGenics Inc
Marino Biotechnology Co Ltd
Medesis Pharma SA
Medical Guidance Systems LLC
Medicenna Therapeutics Corp
Medicon Pharmaceuticals Inc
Medisun Precision Medicine Ltd
MedPacto Inc
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Meryx Inc
Metis Precision Medicine
MetVital Inc
MGC Pharmaceuticals Ltd
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
MimiVax LLC
MiReven Pty Ltd
Molecular Templates Inc
Moleculin Biotech LLC
Multimmune GmbH
Mustang Bio Inc
Mycenax Biotech Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing KAEDI Biotech Inc
Nanomerics Ltd
NanoPharmaceuticals LLC
NantKwest Inc
NatureWise Biotech & Medicals Corp
Nektar Therapeutics
Neon Therapeutics Inc
Neonc Technologies Inc
NewLink Genetics Corp
NMS Group SpA
Northlake International LLC
Northwest Biotherapeutics Inc
Novartis AG
Noxopharm Ltd
Noxxon Pharma AG
NuvOx Pharma LLC
OGD2 Pharma SAS
Omniox Inc
OncoArendi Therapeutics SA
Oncoceutics Inc
Oncologie Inc
Oncology Venture U.S. Inc
Oncolytics Biotech Inc
Onconova Therapeutics Inc
OncoResponse Inc
Oncorus Inc
OncoRx Pharmaceuticals Inc
OncoSynergy Inc
Oncotelic Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
Ossianix Inc
Ovensa Inc
Parabon NanoLabs
Pascal Biosciences Inc
Patrys Ltd
PENAO Pty Ltd
Peptomyc SL
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
PharmAbcine Inc
Pharmicell Co Ltd
Phoenix Biotechnology Inc
Phost'IN SAS
Photonamic GmbH & Co KG
Plex Pharmaceuticals Inc
Prelude Therapeutics Inc
Prestige BioPharma Pte Ltd
Preveceutical Medical Inc
Primevax Immuno Oncology Inc
PTC Therapeutics Inc
Puma Biotechnology Inc
QED Therapeutics Inc
Quadriga BioSciences Inc
Regeneron Pharmaceuticals Inc
Reglagene LLC
Regulus Therapeutics Inc
ReNeuron Group Plc
Rgenix Inc
Richter Gedeon Nyrt
Ridgeline Therapeutics LLC
Rznomics Inc
Salarius Pharmaceuticals Inc
Sanofi
Sapience Therapeutics Inc
Scancell Holdings Plc
Seagull Labs (I) Pvt Ltd
Seneca Therapeutics Inc
Shandong Boan Biological Technology Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shenzhen BinDeBio Ltd
Siam Bioscience Co Ltd
Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
Siena Biotech SpA
SignalChem Lifesciences Corp
SignPath Pharma Inc
Silenseed Ltd
Singh Biotechnology LLC
SixFold Bioscience Ltd
SL Bigen Inc
SL VaxiGen Inc
SOM Biotech SL
Speer Medical Technologies LLC
STAT3 Therapeutics Inc
Stcube Inc
Stella Therapeutics Inc
StemGen SpA
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Susavion Biosciences Inc
Suzhou Stainwei Biotech Inc
Synactix Pharmaceuticals Inc
Synchronicity Pharma Inc
Synermore Biologics Co Ltd
SyntheX Inc
Tactical Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Targinta AB
Telo Therapeutics Inc
Telomium SAS
Terpenoid Therapeutics Inc
The Palo Alto Research Center
TheraBiologics Inc
Theralase Technologies Inc
Therapeia GmbH & Co KG
TheraPten Biosciences Inc
Tmunity Therapeutics Inc
Tocagen Inc
TRACON Pharmaceuticals Inc
Transcode Therapeutics Inc
Transgene SA
Transtarget Inc
Triumvira Immunologics Inc
Turning Point Therapeutics Inc
TVAX Biomedical Inc
Tyme Technologies Inc
Upsher-Smith Laboratories Inc
Vanquish Oncology Inc
Vascular Biogenics Ltd
Vault Pharma Inc
Vaximm AG
VBI Vaccines Inc
VCN Biosciences SL
Vigeo Therapeutics Inc
ViruCure Therapeutics Ltd
Vivacitas Oncology Inc
Wayshine Biopharma Inc
WPD Pharmaceuticals Sp Z oo
X4 Pharmaceuticals Inc
Xonovo Inc
Yooyoung Pharm Co Ltd
Zata Pharmaceuticals Inc
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
ZIOPHARM Oncology Inc


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[多形神経膠芽腫(GBM)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆